Prof Martin Dreyling discusses the safety profile of the BTK inhibitor acalabrutinib in patients with mantle cell lymphoma.

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton ...

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) ...

Currently, Medicare has to wait seven years after a traditional drug gets approved by the U.S. Food and Drug Administration ...

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m.

Lightning Step is proud to share that its Product and Technology team, under the leadership of its CIO & CTO Dr. Martin Ignatovski, has been honored with the Gold Stevie® Award for 2025 Technology ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

BeiGene Ltd (ONC) marks a milestone with its first GAAP profitability, driven by a 49% revenue increase and strong market ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.